AstraZeneca and Ionis Report Unexpected Failure of Heart Disease Drug Candidate
Source Summary
AstraZeneca and Ionis announced an unexpected failure of a heart disease drug candidate in development. The news has drawn attention from Alnylam, which is monitoring the outcome. The article also covers other biotech developments including Roivant's autoimmune drug approval and Cytokinetics' full data release for a heart condition treatment.
Why it matters
Drug development failures in cardiovascular disease treatment affect the pipeline of potential therapies and can influence investment and development strategies across the biotech sector.
